Recent large-scale randomized evidence (TACSI trial, 2025) indicates no incremental benefit of ticagrelor added to aspirin in reducing major cardiovascular events after CABG for acute coronary syndrome compared to aspirin alone.
The combination strategy significantly increases major bleeding risk and net adverse clinical events, cautioning against routine dual antiplatelet therapy post-CABG in this setting.
Current data emphasize the need to individualize antiplatelet regimens post-CABG, balancing ischemic risk and bleeding potential.
